Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease.
Pharma giant Pfizer is injecting $600 million into its venture investment arm in a bid to ramp up its involvement in biotechnology and other emerging growth companies.
The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in a dedicated headquarters for early-stage research.
